巴曲酶治疗中度以上突发性耳聋的疗效观察

摘要

目的：了解巴曲酶治疗中度以上突发性聋（简称突聋）的疗效和预后影响因素，以更好地进行临床治疗。方法回顾性分析2010年10月至2011年10月在该院就诊的56例（共57耳）中度以上平坦型（22耳）和全聋型突聋（35耳）患者的临床资料。其中有33耳常规用药治疗（常规用药组），24耳在常规用药基础上联合应用了巴曲酶治疗（联合组）。结果联合组（66．7％）和常规用药组（33．3％）治疗中度以上突聋患者的总有效率差异有统计学意义（ P＝0．0128）。平坦型与全聋型的总有效率差异有统计学意义（ P＝0．0126）。结论常规用药联合巴曲酶能显著提高中度以上突聋患者的总有效率，疗效优于单用常规药物，且全聋型较平坦型预后差。%Objective To evaluate the effect of treatment with batroxobin on above moderate degree of sudden hearing loss (SHL) ,in order to achieve better clinical therapy .Methods The clinical records of 56 patients (57 ears) with above moderate de‐gree of SHL hospitalized from October 2010 to October 2011 were retrospectively studied .57 ears contained 22 ears of flat type and 35 ears of total type ,33 ears were treated with conventional drugs(conventional group) ,while 24 ears were treated with batroxobin and conventional drugs(combination group) .Results The differences of the total effective rate were statistically significant be‐tween conventional group and conventiona group(P=0 .012 8) and between flat type group and total type group(P=0 .012 6) . Conclusion The combination therapy with batroxobin and conventional drugs can significantly increase the total effective rate of the patients with above moderate degree of SHL ,which is superior to conventional drugs .The prognosis of patients with total type is poor than flat type .